Advancing CHM Research: Dr. Raj Agrawal on Optogenetics | CRF 2025 Interview

Dr. Raj Agrawal, Vice President of Clinical Development at Ray Therapeutics, shares insights into the company’s groundbreaking optogenetic therapies now advancing into clinical trials for retinitis pigmentosa (RP), choroideremia (CHM), Stargardt disease, and age-related macular degeneration (AMD). He highlights key moments from the 2025 Choroideremia Research Foundation (CRF) International Conference, discusses Ray Therapeutics’ innovative work with rods and cones, and explains how patients and families can connect with the company to learn more. Filmed at the 2025 CRF International Conference, June 25–28 at the Radisson Blu, Mall of America, Bloomington, MN. 🔗 Ray Therapeutics: https://raytherapeutics.com/ 🔗 Learn more about CRF: https://www.curechm.org 🔗 Support research: https://curechm.salsalabs.org/donate #CureCHM #Choroideremia #RareDisease #SavingSight #RetinaResearch #RetinitisPigmentosa #RareDiseaseAdvocacy #BlindnessResearch #Ophthalmology #MedicalResearch #EyeHealth #GeneTherapy #Optogenetics #ClinicalTrials #RareDiseaseCommunity #VisionResearch #EndingBlindness